Transdermal delivery of methotrexate: Past, present and future prospects

Therapeutic Delivery

Volumn 3, Issue 3, 2012, Pages 315-325

  Prasad, Rachna ^a,b   Koul, Veena ^a,b  

^a All India Institute of Medical Sciences   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; DICLOFENAC; ESTRADIOL; ETANERCEPT; FENTANYL; GLYCERYL TRINITRATE; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; INSULIN; LIDOCAINE; METHOTREXATE; NICOTINE; OXYBUTYNIN; SCOPOLAMINE; TESTOSTERONE;

ANEMIA; ARTHRITIS; CHRONIC DISEASE; CONTROLLED DRUG RELEASE; CREAM; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG MUSCLE LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTROPORATION; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; HYDROGEL; IONTOPHORESIS; LEUKOPENIA; LIPOPHILICITY; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MICROEMULSION; NANOPHARMACEUTICS; NAUSEA; NEEDLE; NEOPLASM; NEUROTOXICITY; NONHUMAN; OSTEOPOROSIS; PATIENT PARTICIPATION; PHOBIA; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN PERMEABILITY; STOMATITIS; STRATUM CORNEUM; THROMBOCYTOPENIA; ULTRASOUND; VOMITING;

EID: 84858125877     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.3     Document Type: Review

References (73)

1. Denniston PL. Methotrexate in physicians GenRx: the complete drug reference. Denniston Publishing Inc. II1379-II1383 (1996).
2. Stagni G, Shukla C. Pharmacokinetics of methotrexate in rabbit skin and plasma after iv-bolus and iontophoretic administrations. J. Control. Release 93, 283-292 (2003). (Pubitemid 37485950)
3. Bookbinder SA, Espinoza LR, Fenske NA, Germain BF, Vasey FB. Methotrexate: its use in the rheumatic diseases. Clin. Exp. Dermatol. 2, 185-193 (1984). (Pubitemid 14055569)
4. VanDooren-Greebe RJ, Kuijpers ALA, Mulder J, Boo TD, van der Kerhof PCM. Methotrexate revisited: effects of long term treatment in psoriasis. Br. J. Dermatol. 130, 204-210 (1994). (Pubitemid 24204616)
5. Tiwari SB, Kumar BCR, Udupa N, Balchandran C. Topical methotrexate delivered by iontophoresis in the treatment of recalcitrant psoriasis-a case report. Int. J. Dermatol. 42, 157-159 (2003).
6. Chatterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm. Res. 14, 1058-1065 (1997). (Pubitemid 27371407)
7. Gill HS, Prausnitz MR. Does needle size matter? J. Diabetes Sci. Technol. 1, 725-729 (2007).
8. Hwang GC, Lin AY, Chen W, Sharpe RJ. Development and optimization of a methotrexate topical formulation. Drug Dev. Ind. Pharm. 21, 1941-1952 (1995).
9. Shah UU, Roberts M, Gul MO, Tuleu C, Beresford MW. Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs). Int. J. Pharm. 416(1), 1-11 (2011).
10. Cevc G, Vierl U. Nanotechnology and the transdermal route A state of the art review and critical appraisal. J. Control. Release 141, 277-299 (2010).
11. Bajaj S, Whiteman A, Brandner B. Transdermal drug delivery in pain management. Contin. Educ. Anaesth. Crit. Care Pain 11, 39-43 (2011).
12. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 3, 115-124 (2004). (Pubitemid 38239773)
13. Kalia YN, Merino V, Guy RH. Transdermal drug delivery. Clinical aspects. Dermatol. Clin. 16, 289-299 (1998).
14. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm. Res. 13, 1765-1769 (1996). (Pubitemid 27034105)
15. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today 3, 318-326 (2000).
16. Mitragotri S. Breaking the skin barrier. Adv. Drug Deliv. Rev. 56, 555-556 (2004). (Pubitemid 38326931)
17. Prow TW, Grice JE, Lin LL et al. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Del. Rev. 63(6), 470-491 (2011).
18. Williams AC. Structure and function of human skin. In: Transdermal and Topical Drug Delivery-From Theory to Clinical Practice. Pharmaceutical Press London, London, UK 1-25 (2003).
19. Menon GK. New insights into skin structure: scratching the surface. Adv. Drug Deliv. Rev. 54, S3-S17 (2002). (Pubitemid 35379951)
20. Bouwstra JA, Gooris GS, Dubbelaar FER, Ponec M. Phase behaviour of stratum corneum lipid mixtures based on human ceramides: the role of natural and synthetic ceramide I. J. Invest. Dermatol. 118, 606-617 (2002). (Pubitemid 34309979)
21. Guy RH, Hadgraft J. Principles of skin permeability relevant to chemical exposure. In: Dermal and Ocular Toxicology: Fundamentals and Methods. Hobson DW (Ed.). CRC Press, Boca-Raton, FL, USA 221-246 (1991).
22. Scheuplein RJ. Mechanism of percutaneous absorption: I. Routes of penetration and the influence of solubility. J. Invest. Dermatol. 29, 131-149 (1965).
23. Scheuplein RJ. Mechanism of percutaneous absorption: II. Transient diffusion and the relative importance of various routes of skin penetration. J. Invest. Dermatol. 48, 79-88 (1967).
24. Albery WJ, Hadgraft J. Percutaneous absorption: theoretical description. J. Pharm. Pharmacol. 31, 129-139 (1979). (Pubitemid 9124018)
25. Prausnitz MR. Reversible skin permeabilization for transdermal delivery of macromolecules. Crit. Rev. Ther. Drug Carrier Syst. 14, 455-483 (1997). (Pubitemid 28036075)
26. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int. J. Pharm. 212, 101-107 (2001). (Pubitemid 32121955)
27. Fry L, McMinn RM. Topical methotrexate in psoriasis. Arch. Dermatol. 96, 483-488 (1967).
28. Van Scott EJ, Reinertson RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J. Dermatol. 33, 357 (1959).
29. Nurse DS. Effect of antimetabolites on epidermal structures. Arch. Dermatol. 87, 258 (1963).
30. Comaish S, Juhlin L. Site of action of methotrexate in psoriasis. Arch. Derm. 100, 99-105 (1969).
31. Stewart WD, Wallace SM, Reinikis JO. Absorption and local action of methotrexate in human and mouse skin. Arch. Dermatol. 106, 357-361 (1972).
32. Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. 17, 1354-1359 (2000). (Pubitemid 32109486)
33. Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev. 56, 603-618 (2004). (Pubitemid 38326936)
34. Cross SE, Pugh WJ, Hadgraft J, Roberts MS. Probing the effect of vehicles on topical delivery: understanding the basic relationship between solvent and solute penetration using silicone membranes. Pharm. Res. 18(7), 999-1005 (2001). (Pubitemid 32799946)
35. Ball MA, McCullough JL, Weinstein GD. Percutaneous absorption of methotrexate: effect on epidermal DNA synthesis in hairless mice. J. Invest. Dermatol. 79(1), 7-10 (1982). (Pubitemid 12081091)
36. Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch. Dermatol. 125, 227-230 (1989). (Pubitemid 19070209)
37. Lu GW, Jun HW, Dzimianski MT, Qiu HC, McCall JW. Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. Pharm. Res. 12(10), 1474-1477 (1995).
38. Lu G, Jun HW, Suh H. Percutaneous absorption and disposition studies of methotrexate in rabbits and rats. Biopharm. Drug Dispos. 18(5), 409-422 (1997). (Pubitemid 27288371)
39. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm. Acta Helv. 71, 135-140 (1996). (Pubitemid 26281323)
40. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J. Cutan. Med. Surg. 5(4), 299-302 (2001). (Pubitemid 32843784)
41. Sutton L, Swinehart JM, Cato A, Kaplan AS. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int. J. Dermatol. 40, 464-467 (2001). (Pubitemid 32982303)
42. Prasad R, Koul V, Anand S, Khar RK. Effect of DC/mDC iontophoresis and terpenes on transdermal permeation of methotrexate: In vitro Study. Int. J. Pharm. 333, 70-78 (2007). (Pubitemid 46283271)
43. Prasad R, Anand S, Khar RK, Dinda AK, Koul V. Studies on in vitro and in vivo transdermal flux enhancement of methotrexate by a combinational approach in comparison to oral delivery. Drug Dev. Ind. Pharm. 11, 1281-1292 (2009).
44. Knutson K, Krill SL, Zang J. Solvent mediates alteration of the stratum corneum. J. Control. Release 11, 93-103 (1990). (Pubitemid 20070088)
45. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. Percutaneous absorption enhancement of ionic molecule by ethanol-water systems in human skin. Pharm. Res. 7, 762-766 (1990). (Pubitemid 20278377)
46. Rastogi SK, Singh J. Lipid extraction and iontophoretic transport of leuprolide acetate through porcine epidermis. Int. J. Pharm. 215, 241-249 (2001). (Pubitemid 32206621)
47. Javadzadeha Y, Hamishehkarb H. Enhancing percutaneous delivery of methotrexate using different types of surfactants. Coll. Surfaces B. Biointerfaces 82, 422-426 (2011).
48. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int. J. Pharm. 215, 57-65 (2001). (Pubitemid 32206604)
49. Chandak AR, Verma PR. Design and development of hydroxypropyl methycellulose (HPMC) based polymeric films of methotrexate: physicochemical and pharmacokinetic evaluations. Yakugaku Zasshi 128(7), 1057-1066 (2008). (Pubitemid 351955250)
50. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 270, 119-125 (2004). (Pubitemid 38077093)
51. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release 123, 148-154 (2007). (Pubitemid 47562141)
52. Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int. J. Pharm. 401, 72-78 (2010).
53. Singka GSL, Samah NAA, Zulfakar MH, Yurdasiper A, Heard CM. Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Eur. J. Pharm. Biopharm. 76, 275-281 (2010).
54. Jadoul A, Bouwstra J, Preat V. Effects of iontophoresis and electroporation on the stratum corneum: review of the biophysical studies. Adv. Drug Del. Rev. 35, 89-105 (1999). (Pubitemid 29046388)
55. Leduc S. Introduction of medicinal substances into the depth of tissues by electric current. Ann. d' Electrobiol. 3, 545-560 (1900).
56. Kalia Y, Nonato LB, Guy RH. The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and transepidermal water loss. Pharm. Res. 13, 957-961 (1996).
57. Hinsberg WHM, Craane-van, Verhoef JC et al. Electroperturbation on the human skin barrier in vitro (II): effects on stratum corneum lipid ordering and ultrastructure. Microsc. Res. Tech. 37, 200-213 (1997).
58. Singh J, Singh S. Transdermal iontophoresis: effect of penetration enhancer and iontophoresis on drug transport and surface characteristics of human epidermis. Curr. Prob. Dermatol. 22, 179-183 (1995).
59. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev. 35, 61-76 (1999). (Pubitemid 29046386)
60. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res. Tech. 14(3), 249-260 (2008).
61. Prausnitz MR. Electroporation. In: Electronically Controlled Drug Delivery. Berner B, Dinh SM (Eds). CRC Press, Boca Raton, FL, USA 185-214 (1998).
62. Denet AR, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56, 659-674 (2004). (Pubitemid 38326938)
63. Wong TW, Zhao YL, Sen A, Hui SW. Pilot study of topical delivery of methotrexate by electroporation. Bri. J. Dermatol. 152(3), 524-530 (2005). (Pubitemid 40547127)
64. Wong TW, Chen CH, Huang CC, Lin CD, Hui SW. Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J. Control. Release 110, 557-565 (2006).
65. Cleary G. Microneedles for drug delivery. Pharm. Res. 28, 1-6 (2011).
66. Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56, 581-587 (2004). (Pubitemid 38326934)
67. Sachdeva V, Banga AK. Microneedles and their applications. Recent Pat. Drug Delivery Formulation 5, 95-132 (2011).
68. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 87(8), 922-925 (1998). (Pubitemid 28381247)
69. Migalska K, Morrow DI, Garland MJ, Thakur R, Woolfson AD, Donnelly RF. Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery. Pharm. Res. 28(8), 1919-1930 (2011).
70. Fukushima K, Ise A, Morita H et al. Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. Pharm. Res. 28, 7-21 (2011).
71. Sullivan SP, Koutsonanos DG, Martin MD et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16, U915-U116 (2010).
72. Harvey A, Kaestner S, Sutter D, Harvey N, Mikszta J, Pettis R. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm. Res. 28, 107-116 (2011).
73. Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J. Pharm. Pharmacol. 60, 27-33 (2008).